nach oben

Erschienen in:

18.01.2022 | Original Article

Volumetric changes within hippocampal subfields in Alzheimer’s disease continuum

Erschienen in: Neurological Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Neurodegeneration in Alzheimer’s disease continuum (ADC) starts from the transentorhinal cortex and progresses within hippocampal circuitry following the connectivity of its subfields transsynaptically. We aimed to track volumetric changes of the hippocampal subfields by comparing three stages of the ADC. MRI data of 15 patients diagnosed with Alzheimer’s disease dementia (ADD), 15 patients with amnestic mild cognitive impairment (MCI), and 15 individuals with subjective cognitive impairment (SCI) were analyzed. The hippocampal formation was subdivided into CA1, CA3, subiculum (SUB), and dentate gyrus (DG) using FreeSurfer and volumetric values were obtained. The volumetric values were analyzed with ANCOVA and intracranial volume was selected as a covariate. ANCOVA results of the hippocampal subfields displayed statistically significant differences among the three groups in bilateral CA1, SUB, and DG volumes (Right CA1: F = 7.316, p = 0.002; left CA1: F = 6.768, p = 0.003; right SUB: F = 9.390, p < 0.001; left SUB: F = 5.925, p = 0.005; right DG: F = 9.469, p < 0.001; left DG: F = 9.354, p < 0.001), while CA3 volumes were not significantly different among the groups. Post hoc comparisons revealed that volume reductions in bilateral CA1, DG, and SUB were present in ADD compared to both MCI and SCI groups. No significant volumetric changes were found between the SCI and MCI groups. While our results are generally consistent with the literature in terms of the CA1 and SUB findings, they additionally point to the importance of the significant volume loss in DG and the resilience of the CA3 sector.

Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C (2017) Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci 24:46–54. https://doi.org/10.1159/000464422CrossRefPubMedPubMedCentral

Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA (2008) The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30:58–69. https://doi.org/10.1159/000115751CrossRefPubMedPubMedCentral

Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F, S.C.D.I. (SCD-I.W. Group (2017) Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 13:296–311. https://doi.org/10.1016/j.jalz.2016.09.012CrossRefPubMed

Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, Monteiro I, Torossian C, Vedvyas A, Ashraf N, Jamil IA, de Leon MJ (2008) The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease. Alzheimers Dement 4:S98–S108. https://doi.org/10.1016/j.jalz.2007.11.017CrossRefPubMed

Jessen F, Wolfsgruber S, Wiese B, Bickel H, Mösch E, Kaduszkiewicz H, Pentzek M, Riedel-Heller SG, Luck T, Fuchs A, Weyerer S, Werle J, van den Bussche H, Scherer M, Maier W, Wagner M (2014) AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement 10:76–83. https://doi.org/10.1016/j.jalz.2012.09.017CrossRefPubMed

DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 14:32. https://doi.org/10.1186/s13024-019-0333-5CrossRefPubMedPubMedCentral

Femir-Gurtuna B, Kurt E, Ulasoglu-Yildiz C, Bayram A, Yildirim E, Soncu-Buyukiscan E, Bilgic B (2020) White-matter changes in early and late stages of mild cognitive impairment. J Clin Neurosci 78:181–184. https://doi.org/10.1016/j.jocn.2020.04.078CrossRefPubMed

Jack CR, Petersen RC, O’brien PC, Tangalos EG (1992) MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 42:183. https://doi.org/10.1212/wnl.42.1.183CrossRefPubMed

Jack CR, Petersen RC, Xu YC, Waring SC, O’Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E (1997) Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 49:786–794. https://doi.org/10.1212/wnl.49.3.786CrossRefPubMed

10.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55:967–972. https://doi.org/10.1136/jnnp.55.10.967CrossRefPubMedPubMedCentral

11.

Jack CR, Barkhof F, Bernstein MA, Cantillon M, Cole PE, DeCarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB (2011) Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimer’s Dement 7:474–485. https://doi.org/10.1016/j.jalz.2011.04.007CrossRef

12.

Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–284. https://doi.org/10.1016/0197-4580(95)00021-6CrossRefPubMed

13.

Wilson RS, Li Y, Aggarwal NT, McCann JJ, Gilley DW, Bienias JL, Barnes LL, Evans DA (2006) Cognitive decline and survival in Alzheimer’s disease. Int J Geriatr Psychiatry 21:356–362. https://doi.org/10.1002/gps.1472CrossRefPubMed

14.

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. https://doi.org/10.1007/BF00308809CrossRefPubMed

15.

De Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697. https://doi.org/10.1016/j.neuron.2011.11.033CrossRefPubMedPubMedCentral

16.

Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA (2011) A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci 12:585–601. https://doi.org/10.1038/nrn3085CrossRefPubMedPubMedCentral

17.

Insausti R, Amaral DG (2012) Hippocampal formation. In: Elsevier Inc., pp 896–942 BT-The Human Nervous System. https://doi.org/10.1016/B978-0-12-374236-0.10024-0.

18.

Wisse LEM, Daugherty AM, Olsen RK, Berron D, Carr VA, Stark CEL, Amaral RSC, Amunts K, Augustinack JC, Bender AR (2017) A harmonized segmentation protocol for hippocampal and parahippocampal subregions: why do we need one and what are the key goals? Hippocampus 27:3–11. https://doi.org/10.1002/hipo.22671CrossRefPubMed

19.

Parker TD, Cash DM, Lane CAS, Lu K, Malone IB, Nicholas JM, James S-N, Keshavan A, Murray-Smith H, Wong A (2019) Hippocampal subfield volumes and pre-clinical Alzheimer’s disease in 408 cognitively normal adults born in 1946. PLoS ONE 14:e0224030. https://doi.org/10.1371/journal.pone.0224030CrossRefPubMedPubMedCentral

20.

Yushkevich PA, Pluta JB, Wang H, Xie L, Ding S, Gertje EC, Mancuso L, Kliot D, Das SR, Wolk DA (2015) Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Hum Brain Mapp 36:258–287. https://doi.org/10.1002/hbm.22627CrossRefPubMed

21.

Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. https://doi.org/10.1016/0022-3956(75)90026-6CrossRefPubMed

22.

Morris JC (1993) The Clinical Dementia Rating (CDR). Neurology 43:2412 LP-2412-a. https://doi.org/10.1212/WNL.43.11.2412-aCrossRef

23.

Ivnik RJ, Smith GE, Lucas JA, Tangalos EG, Kokmen E, Petersen RC (1997) Free and cued selective reminding test: MOANS norms. J Clin Exp Neuropsychol 19:676–691. https://doi.org/10.1080/01688639708403753CrossRefPubMed

24.

Buschke H (1984) Cued recall in amnesia. J Clin Neuropsychol 6:433–440. https://doi.org/10.1080/01688638408401233CrossRefPubMed

25.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJ, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005CrossRefPubMedPubMedCentral

26.

Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194. https://doi.org/10.1111/j.1365-2796.2004.01388.xCrossRefPubMed

27.

Grober E, Sanders AE, Hall C, Lipton RB (2010) Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord 24:284–290. https://doi.org/10.1097/WAD.0b013e3181cfc78bCrossRefPubMedPubMedCentral

28.

Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33:341–355. https://doi.org/10.1016/s0896-6273(02)00569-xCrossRefPubMed

29.

Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 9:179–194. https://doi.org/10.1006/nimg.1998.0395CrossRefPubMed

30.

Iglesias JE, Augustinack JC, Nguyen K, Player CM, Player A, Wright M, Roy N, Frosch MP, McKee AC, Wald LL, Fischl B, Van Leemput K (2015) A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: application to adaptive segmentation of in vivo MRI. Neuroimage 115:117–137. https://doi.org/10.1016/j.neuroimage.2015.04.042CrossRefPubMed

31.

Fischl B, Salat DH, van der Kouwe AJW, Makris N, Ségonne F, Quinn BT, Dale AM (2004) Sequence-independent segmentation of magnetic resonance images. Neuroimage. 23(Suppl 1):S69-84. https://doi.org/10.1016/j.neuroimage.2004.07.016CrossRefPubMed

32.

Parker TD, Slattery CF, Yong KXX, Nicholas JM, Paterson RW, Foulkes AJM, Malone IB, Thomas DL, Cash DM, Crutch SJ, Fox NC, Schott JM (2019) Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer’s disease. NeuroImage Clin 21:101632. https://doi.org/10.1016/j.nicl.2018.101632CrossRefPubMed

33.

Hett K, Ta V-T, Catheline G, Tourdias T, Manjón JV, Coupé P (2019) Multimodal hippocampal subfield grading for Alzheimer’s disease classification. Sci Rep 9:1–16. https://doi.org/10.1038/s41598-019-49970-9CrossRef

34.

Carlesimo GA, Piras F, Orfei MD, Iorio M, Caltagirone C, Spalletta G (2015) Atrophy of presubiculum and subiculum is the earliest hippocampal anatomical marker of Alzheimer’s disease. Alzheimer’s Dement, Diagnosis Assess Dis Monit 1:24–32. https://doi.org/10.1016/j.dadm.2014.12.0015CrossRef

35.

Zhao W, Wang X, Yin C, He M, Li S, Han Y (2019) Trajectories of the hippocampal subfields atrophy in the Alzheimer’s disease: a structural ımaging study. Front Neuroinform 13:13. https://doi.org/10.3389/fninf.2019.00013CrossRefPubMedPubMedCentral

36.

Tang X, Holland D, Dale AM, Younes L, Miller MI, Initiative ADN (2014) Shape abnormalities of subcortical and ventricular structures in mild cognitive impairment and Alzheimer’s disease: detecting, quantifying, and predicting. Hum Brain Mapp 35:3701–3725. https://doi.org/10.1002/hbm.22431CrossRefPubMedPubMedCentral

37.

Frisoni GB, Ganzola R, Canu E, Rüb U, Pizzini FB, Alessandrini F, Zoccatelli G, Beltramello A, Caltagirone C, Thompson PM (2008) Mapping local hippocampal changes in Alzheimer’s disease and normal ageing with MRI at 3 Tesla. Brain 131:3266–3276. https://doi.org/10.1093/brain/awn280CrossRefPubMed

38.

Parnetti L, Chipi E, Salvadori N, D’Andrea K, Eusebi P (2019) Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis. Alzheimers Res Ther 11:7. https://doi.org/10.1186/s13195-018-0459-7CrossRefPubMedPubMedCentral

39.

Hwang J, Jeong JH, Yoon SJ, Park KW, Kim E-J, Yoon B, Jang J-W, Kim HJ, Hong JY, Lee J-M, Park H, Kang J-H, Choi Y-H, Park G, Hong J, Byun MS, Yi D, Kim YK, Lee DY, Choi SH (2019) Clinical and biomarker characteristics according to clinical spectrum of Alzheimer’s disease (AD) in the validation cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. J Clin Med 8:341. https://doi.org/10.3390/jcm8030341CrossRefPubMedCentral

40.

Berron D, Schütze H, Maass A, Cardenas-Blanco A, Kuijf HJ, Kumaran D, Düzel E (2016) Strong evidence for pattern separation in human dentate gyrus. J Neurosci 36:7569–7579. https://doi.org/10.1523/JNEUROSCI.0518-16.2016CrossRefPubMedPubMedCentral

Titel: Volumetric changes within hippocampal subfields in Alzheimer’s disease continuum
Publikationsdatum: 18.01.2022
Erschienen in: Neurological Sciences / Ausgabe 7/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-05890-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

The association between stroke and COVID-19-related mortality: a systematic review and meta-analysis based on adjusted effect estimates

Inattentional blindness to DWI lesions in spontaneous intracerebral hemorrhage

Terson syndrome in reverse: intraventricular haemorrhage following primary intraocular haemorrhage

Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan

Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: a randomized, placebo-controlled trial